Paris (France), 12 October 2018 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced that cabozantinib (Cabometyx^®), irinotecan liposome injection (Onivyde^®), lanreotide (Somatuline^®) and the combination of lanreotide and telotristat (Xermelo^®) are the subject of 12 presentations at the 2018 European Society for Medical Oncology (ESMO) annual congress. The meeting takes place in Munich, Germany, October 19-23, 2018.

 

“Ipsen has had a momentous 12 months since ESMO 2017, particularly with the positive regulatory milestones achieved for Cabometyx^® in renal cell and hepatocellular carcinoma, and for Xermelo^® in neuroendocrine tumours. Our story continues with a strong presence at ESMO 2018 with 12 posters presenting meaningful data for patients with hepatocellular carcinoma, renal cell carcinoma, medullary thyroid cancer, pancreatic cancer and neuroendocrine tumours,” said Alexandre Lebeaut M.D, Executive Vice President, Research & Development and Chief Scientific Officer, Ipsen.

“Our oncology products, notably Cabometyx^®, Onivyde^®, Somatuline^® and Xermelo^® have been evaluated by scientific teams around the world; either directly by investigators, by our partners, or by Ipsen, and results from some of these investigations will be shared at ESMO 2018. We are committed in our efforts against cancer, and through our interactions at ESMO will continue to advance innovation for patient care in oncology”, added Dr Lebeaut.

 

Cabozantinib (Cabometyx^®) will be featured in 5  posters:

Poster session, Sunday October 21^st, 13:15 ‐ 14:15, Hall A3

 CELESTIAL study

• [Poster 702P] Outcomes by baseline alpha-fetoprotein (AFP) levels in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (HCC) (Kelley et al.)

Presenting author: R.K. Kelley [Sponsor: Exelixis]

 

• [Poster 703P] Assessment of disease burden in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC) (Blanc et al.)

Presenting author: JF Blanc [Sponsor: Exelixis]

 

• [Poster 704P] Outcomes by prior transarterial chemoembolization (TACE) in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) (Yau et al.)

Presenting author: T Yau [Sponsor: Exelixis]

 

Poster session, Monday October 22^nd, 13:15 ‐ 14:15, Hall A3

COSMIC-021 study (Cabozantinib + atezolizumab)

• [Poster 872P] Phase 1b study (COSMIC-021) of cabozantinib in combination with atezolizumab in solid tumors: Results of the dose escalation stage in patients with treatment-naïve advanced RCC (Agarwal et al.)

Presenting author: N Agarwal [Sponsor: Exelixis]

 

Poster session, Sunday October 21^st, 13:15 ‐ 14:15, Hall A3

EXAMINER study

• [Poster 129TiP] A noninferiority trial of cabozantinib (C) comparing 140 mg vs 60 mg orally per day to evaluate the efficacy and safety in patients (pts) with progressive, metastatic medullary thyroid cancer (MTC) (Krajewska et al.)

Presenting author: J Krajewska [Sponsor: Exelixis]

 

Poster session, Sunday October 21^st, 13:15 ‐ 14:15, Hall A3

Irinotecan liposome injection (Onivyde^®) will be featured in 4 presentations:

• [Poster 749P] The prognostic value of the Modified Glasgow Prognostic Score (mGPS) in predicting overall survival (OS) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) receiving liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV). (Chen, et al.)

Presenting author: L-T Chen [Sponsor: Ipsen]

• [Poster 734P] Impact of dose reduction or dose delay on the efficacy of liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV): Survival analysis from NAPOLI-1. (Chen, et al.)

Presenting author: L-T Chen [Sponsor: Ipsen]

• [Poster 735P] Real-world dosing patterns of patients (pts) with metastatic pancreatic cancer (mPC) treated with liposomal irinotecan (nal-IRI) in US oncology clinics. (Ahn, et al.)

Presenting author: D Ahn [Sponsor: Ipsen]

• [Poster 733P] NAPOLI-1 Phase 3 trial outcomes by prior surgery, and disease stage, in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). (Macarulla, et al.)

Presenting author: T Macarulla [Sponsor: Shire]

 

Poster session, Sunday October 21^st, 13:15 ‐ 14:15, Hall A3

Lanreotide (Somatuline^®) will be featured in 2 presentations:

 PRELUDE (TGR)

• [Poster 1331P] Tumour growth rate (TGR) when using lanreotide Autogel® (LAN) before, during and after peptide receptor radionuclide therapy (PRRT) in advanced neuroendocrine tumours (NETs). (Prasad, et al.)

Presenting author: V Prasad [Sponsor: Ipsen]

 

Poster session, Sunday October 21^st, 13:15 ‐ 14:15, Hall A3

 CLARINET (diabetes)

• [Poster 1319P] Post-hoc analysis of CLARINET phase III study to investigate the influence of diabetic status on progression-free survival (PFS) of patients with neuroendocrine tumours (NETs) treated with lanreotide (LAN) or placebo (PBO). (Pusceddu, et al.)

Presenting author: V Pusceddu [Sponsor: Ipsen]

 

Poster session, Sunday October 21^st, 13:15 ‐ 14:15, Hall A3

Lanreotide (Somatuline^®) & telotristat (Xermelo^®) will be featured in 1 presentation:

 TELESTAR & TELECAST (LAN patients)

• [Poster 4378P] Efficacy and safety of telotristat ethyl (TE) in combination with lanreotide (LAN) in patients with a neuroendocrine tumour and carcinoid syndrome (CS) diarrhoea (CSD): Meta-analysis of phase 3 double-blind placebo (PBO)-controlled TELESTAR and TELECAST studies. (Hörsch, et al.)

Presenting author: D Hörsch [Sponsor: Ipsen]